Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Receivables - Net: 2016-2025

Historic Receivables - Net for Collegium Pharmaceutical (COLL) over the last 10 years, with Sep 2025 value amounting to $233.9 million.

  • Collegium Pharmaceutical's Receivables - Net rose 2.40% to $233.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $233.9 million, marking a year-over-year increase of 2.40%. This contributed to the annual value of $228.5 million for FY2024, which is 27.30% up from last year.
  • As of Q3 2025, Collegium Pharmaceutical's Receivables - Net stood at $233.9 million, which was up 9.82% from $213.0 million recorded in Q2 2025.
  • Over the past 5 years, Collegium Pharmaceutical's Receivables - Net peaked at $233.9 million during Q3 2025, and registered a low of $90.1 million during Q2 2021.
  • Over the past 3 years, Collegium Pharmaceutical's median Receivables - Net value was $183.9 million (recorded in 2024), while the average stood at $199.9 million.
  • Per our database at Business Quant, Collegium Pharmaceutical's Receivables - Net skyrocketed by 119.21% in 2022 and then fell by 15.20% in 2023.
  • Collegium Pharmaceutical's Receivables - Net (Quarterly) stood at $105.8 million in 2021, then skyrocketed by 73.01% to $183.1 million in 2022, then decreased by 1.96% to $179.5 million in 2023, then rose by 27.30% to $228.5 million in 2024, then increased by 2.40% to $233.9 million in 2025.
  • Its Receivables - Net stands at $233.9 million for Q3 2025, versus $213.0 million for Q2 2025 and $228.7 million for Q1 2025.